Only complete language versions are shown.
When planning first-line treatment for persistent, recurrent or metastatic cervical cancer, China's cadonilimab bispecific antibody combination may be considered even with negative PD-L1. Wu Xiaohua's team at Fudan University Shanghai Cancer Center has pivotal study experience. You can enquire about the regimen and ongoing treatment budget; patient acceptance and supply must be confirmed.
Free initial service consultation · Understand your options and budget before you travel
This is the analysis published in 2024; the comparator was the same chemotherapy ± bevacizumab plus placebo, not other immunotherapy drugs. View the evidence
Efficacy figures come from the 2024 COMPASSION-16 analysis, not a head-to-head comparison with other immunotherapies. Prices were published by Tungwah on 2026-06-26, not current international patient quotes or full treatment costs. View sources
In May 2025, China approved cadonilimab with platinum-based chemotherapy, with or without bevacizumab. Negative PD-L1 need not be the sole reason to rule out this pathway.
Cadonilimab targets both PD-1 and CTLA-4, and a Chinese randomised phase III study supports its first-line combination use. Not being limited to PD-L1-positive disease does not make it suitable for everyone.
Bevacizumab is optional. Weigh bleeding, fistula risk, prior pelvic radiotherapy and organ function to balance treatment opportunity and safety.
Estimated for fully self-funded foreign patients without Chinese health insurance or free-drug assistance; 60kg is only a dosing example. Chemotherapy, optional bevacizumab and monitoring are additional, and the budget must cover continued treatment.
Published by Tungwah on 2026-06-26; not an international patient quote. The example uses whole vials every 3 weeks. Weight, treatment duration and combination drugs determine the total.
Clarifying your disease type and previous treatment helps establish whether this option could form part of a plan for you.
On a backbone of the same platinum-based chemotherapy, with or without bevacizumab, COMPASSION-16 compared added cadonilimab with placebo. This cannot establish superiority to other immunotherapy medicines.
Ongoing treatment and reassessment are needed. Response is not a reason to stop medication yourself; bispecific antibodies can still cause immune toxicity.
Explore Shanghai teams whose research and clinical focus relate to your condition and may warrant further discussion.
Principal investigator of COMPASSION-16
Wu Xiaohua of Fudan University Shanghai Cancer Center was principal investigator of COMPASSION-16, with experience in the first-line cervical cancer population described here. The team may be relevant for a combination treatment consultation; patient acceptance, supply and scheduling require separate confirmation.
Published research and clinical information can inform hospital selection; specific doctors, drug availability, international clinic charges and appointment dates are subject to confirmation by the hospital.
Tell us your diagnosis, previous treatments and main concerns. We help you communicate about Shanghai consultation requirements, budgets and travel arrangements.
You do not need to arrange new tests yourself for an initial consultation.
Costs, potential benefit and further treatment deserve specific answers before departure.
You can discuss the bispecific antibody combination on this page; approval does not require positive PD-L1. First-line persistent, recurrent or metastatic cervical cancer criteria and safety requirements still apply. If cure remains possible, local treatment should be assessed first.
Not necessarily. Bleeding or fistula risks and prior pelvic radiotherapy particularly require careful consideration; the team should decide based on your circumstances.
Not directly. Provide previous chemoradiotherapy, immunotherapy and recurrence intervals so the team can assess subsequent options. A first-line study does not establish the same benefit from switching after immunotherapy resistance.
Breathlessness, persistent diarrhoea or jaundice may indicate immune-related inflammation. Fever or bleeding requires prompt assessment for infection or low blood counts. Bispecific antibodies can still cause immune toxicity, and response is not a reason to stop treatment yourself.
Starting with your condition and budget, we help communicate about consultations and treatment arrangements in Shanghai.
The initial service consultation is free; the treating doctor assesses your specific medical plan.
Information is compiled from public approval documents, studies and prices and does not replace an individual medical assessment. Research and cost figures each have a defined scope; published prices are not personal international patient quotes. Costs are discussed on a self-funded basis without Chinese health insurance or free-drug assistance.
Portrait photograph:Hospital's public professional profile. Public accessibility does not constitute a commercial image licence.